PMID- 15334857
OWN - NLM
STAT- MEDLINE
DCOM- 20041104
LR  - 20190917
IS  - 0277-0008 (Print)
IS  - 0277-0008 (Linking)
VI  - 24
IP  - 8 Pt 2
DP  - 2004 Aug
TI  - Anticoagulant prophylaxis in medical patients: an objective assessment.
PG  - 120S-126S
AB  - Venous thromboembolism (VTE) is a clinically silent and potentially fatal disease 
      that manifests as deep vein thrombosis (DVT) and pulmonary embolism. Venous 
      thromboembolism remains a serious public health challenge, with an 
      ever-increasing odds ratio of occurrence given the aging population in the United 
      States. This article reviews the epidemiology of VTE; risk factor identification 
      and stratification as a means of advancing awareness, prevention, and detection 
      of VTE; and prophylaxis options and their outcomes, particularly administration 
      of unfractionated heparin (UFH) 5000 U subcutaneously every 12 versus 8 hours in 
      the at-risk medical patient population. The important studies comparing outcomes 
      of these different UFH dosing regimens compared with placebo and 
      low-molecular-weight heparins also are discussed. Consensus recommendations 
      shaping contemporary clinical practice guidelines in this setting are 
      highlighted. A systemwide approach to treatment of all medical patients who are 
      risk stratified and receiving appropriate pharmacologic prophylaxis is 
      recommended.
FAU - Deitelzweig, Steven
AU  - Deitelzweig S
AD  - Ochsner Clinic Foundation, Section of Hospital-Based Internal Medicine, New 
      Orleans, Louisiana 70121, USA. sdeitelzweig@ochsner.org
FAU - Groce, James B 3rd
AU  - Groce JB 3rd
CN  - Heparin Consensus Group
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Pharmacotherapy
JT  - Pharmacotherapy
JID - 8111305
RN  - 0 (Fibrinolytic Agents)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Heparin/adverse effects/*therapeutic use
MH  - Heparin, Low-Molecular-Weight/therapeutic use
MH  - Humans
MH  - Practice Guidelines as Topic
MH  - Randomized Controlled Trials as Topic
MH  - Risk Factors
MH  - Venous Thrombosis/*prevention & control
RF  - 31
EDAT- 2004/09/01 05:00
MHDA- 2004/11/05 09:00
CRDT- 2004/09/01 05:00
PHST- 2004/09/01 05:00 [pubmed]
PHST- 2004/11/05 09:00 [medline]
PHST- 2004/09/01 05:00 [entrez]
AID - 10.1592/phco.24.12.120s.36115 [doi]
PST - ppublish
SO  - Pharmacotherapy. 2004 Aug;24(8 Pt 2):120S-126S. doi: 
      10.1592/phco.24.12.120s.36115.